Project Title
Biomarker development for combined PD1+LAG3 inhibition in RRD glioblastoma
Layman’s summary
Glioblastoma (GBM) is the leading cause of cancer-related death in children, adolescents, and young adults. Traditional therapies like surgery, chemotherapy, and radiation fail to cure these patients. Dr. Das’s international consortium identified a GBM subtype arising from errors during DNA replication, which accumulate many ‘mutations’. Dr. Das obtained approval to treat selected children with a new therapy, which shows signs of effectiveness. New ‘biomarkers’ will be analyzed to validate the immune response of these patients. If successful, this combination will be tested in a larger clinical trial and become the standard of care for this previously deadly disease. This grant was co-funded through a partnership with Kindred Foundation.
Anirban Das
This Project By The Numbers
-
Years Active3 years
-
Amount Awarded$100,000
-
InstitutionSickKids Toronto
Additional CKc Funded Research
